Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential

#TNGX Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

www.stocktitan.net/news/TNGX/tango-therapeu...

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor Tango Therapeutics, Inc. (NASDAQ: TNGX), a

#TNGX Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

www.stocktitan.net/news/TNGX/tango-therapeu...

#Stock #Market continues to build upwards. Was skeptical of last week's broad rally b/c below average volume. But #semis rotation (from #NVDA #AMD to #INTC #AVGO #MRVL), maybe tech legs here. Focus list is sector-broad, good sign.
Longs: #SOXL #ONDS
Focus: #QBTS #REAL #TNGX #AMTM #NXT #OPEN #LMND

Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights Tango Therapeutics (NASDAQ: TNGX) reported Q3 2025 results and operational updates on Nov 4, 2025. Key clinical data include vopimetostat mPFS 7.2 months in 2L MTAP-del pancreatic cancer and a 49% ORR with mPFS 9.1 months in a 13‑histology MTAP-del cohort. Vopimetostat combination studies with Revolution Medicines’ RAS(ON) inhibitors are ongoing with initial data expected in 2026. TNG456 received FDA Orphan Drug Designation for malignant glioma. TNG260 showed a subgroup mPFS of 27 weeks in STK11mut/KRAS WT lung cancer. Financially, the company reported Q3 net income $15.9M and held $152.8M cash as of Sept 30, 2025, plus ~$212M net proceeds from an October 2025 financing that extends runway into 2028.

#TNGX Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

www.stocktitan.net/news/TNGX/tango-therapeu...

Most Searched, Thursday October 23, 2025 – Crystal Equity Research

Most searched small-cap stocks, Thu Oct 23rd - #DVLT #TNGX #RXRX #LAES #ONDS #SGBX #NVTS #DNN #AREB #TE #VTYX #WRD #VLRS #UAMY #INOD #BYND #BTCS #BORR #DNUT #APP - More: crystalequityresearch.com/most-searche... - #smallcap

Tango Therapeutics Announces $225 Million Financing Financing participants include Farallon Capital Management, TCGX, Balyasny Asset Management, Woodline Partners LP, Nextech, Invus, Adage Capital Management LP, Boxer Capital Management, Logos Capital, Nantahala Capital, accounts advised by T. Rowe Price Investment Management, Inc., and a large

#TNGX Tango Therapeutics Announces $225 Million Financing

www.stocktitan.net/news/TNGX/tango-therapeu...

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers Tango Therapeutics (NASDAQ: TNGX) reported positive Phase 1/2 data for vopimetostat (TNG462) in MTAP-deleted cancers dated October 23, 2025. Across 94 evaluable patients, the overall ORR is 27%, disease control rate 78%, and median PFS 6.4 months. In 2L MTAP-del pancreatic cancer (n=39 at active doses) ORR 25% and mPFS 7.2 months; company plans a ~300-patient global randomized pivotal trial in 2026 at the FDA-aligned dose 250 mg QD. A histology-agnostic cohort (excluding pancreatic, lung, sarcoma) showed ORR 49% and mPFS 9.1 months. Safety at 250 mg QD was generally tolerable; most common TRAEs were nausea, anemia, fatigue, dysgeusia, thrombocytopenia.

#TNGX Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

www.stocktitan.net/news/TNGX/tango-therapeu...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#VZLA, #FLY, #ACHV, #NEXT, #TNGX

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #VZLA 4.5x
2. #FLY 4.4x
3. #ACHV 4.2x
4. #NEXT 2.8x
5. #TNGX 2.1x

#OptionFlow #OptionsTrading #Trading

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights Tango Therapeutics (NASDAQ:TNGX) reported Q2 2025 financial results and pipeline updates. The company achieved key milestones in its clinical programs, including first patient dosing in two trials: a combination trial of TNG462 with Revolution Medicines' RAS(ON) inhibitors and a Phase 1/2 trial of TNG456 for glioblastoma.Financial highlights include $180.8 million in cash reserves expected to fund operations into Q1 2027. Q2 2025 showed revenue of $3.2 million, down from $7.8 million in Q2 2024, and a net loss of $38.9 million ($0.35 per share). The company's collaboration with Gilead will conclude its research portion early, resulting in $53.8 million revenue recognition in Q3 2025.

#TNGX Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

www.stocktitan.net/news/TNGX/tango-therapeu...

Illustration of a cancer cell being attacked and breaking apart, symbolizing targeted cancer therapy by Tango Therapeutics.

Tango Therapeutics (NASDAQ: #TNGX) has dosed the first patient in its Phase 1/2 trial of TNG462 plus Revolution Medicines’ RAS inhibitors for MTAP-deleted pancreatic and lung cancers.
#TangoTherapeutics
prismmarketview.com/new-tango-tr...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Tue Jun 3rd - #CIFR #RSLS #VLRS #TNGX #SEDG #PSIX #NVTS #MCTR #LTBR #LEU #KULR #KIDZ #GRYP #DNN #CGEN #CATX #BTCS #ASPI #APLD #AI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Tango Launches Phase 1/2 Trial for Brain Cancer Drug: New Hope for Deadly Glioblastoma Treatment New brain-penetrant drug targets aggressive glioblastoma with 45% genetic marker. Phase 1/2 trial begins for patients with few options. See trial details.

#TNGX Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

www.stocktitan.net/news/TNGX/tango-therapeu...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Mon May 19th - #NLSP #MDB #MDCX #ENVB #DVLT #TNGX #QMCO #NVAX #LAES #KTCC #INV #GAN #FTEK #FENC #CXAI #BCLI #AGAE #SOC #PGRE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights Tango Therapeutics (NASDAQ: TNGX) reported Q1 2025 financial results and pipeline updates. The company's lead candidate TNG462, a PRMT5 inhibitor, is progressing with data updates expected in 2H 2025, focusing on pancreatic and lung cancer. A combination trial with Revolution Medicines' RAS(ON) inhibitors is set to begin in Q2 2025. The company reported $216.7 million in cash, extending runway into Q1 2027 through reduced preclinical spending. Q1 2025 financials showed collaboration revenue of $5.4 million (down from $6.5M in Q1 2024), R&D expenses of $36.4 million (down from $38.1M), and a net loss of $39.9 million ($0.36 per share). Other pipeline developments include TNG456 for glioblastoma, TNG260 showing proof-of-mechanism in NSCLC trials, and TNG961, a novel HBS1L molecular glue degrader for FOCAD-deleted cancers.

#TNGX Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

www.stocktitan.net/news/TNGX/tango-therapeu...

Breakthrough: Novel Brain-Penetrant Cancer Drugs Target Previously Untreatable Tumors Revolutionary precision oncology pipeline shows strong efficacy in brain cancer treatment. New data reveals potential for combination therapy in MTAP-deleted cancers. Full analysis inside.

#TNGX Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

www.stocktitan.net/news/TNGX/tango-therapeu...

Can Tango's Cancer Breakthroughs in Pancreatic and Lung Cancer Outweigh Its Growing Losses? TNG462 shows durable responses in pancreatic and lung cancers with FDA Orphan Drug Designation. New Eli Lilly collaboration advances TNG456 with cash runway into 2026.

#TNGX Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights 

www.stocktitan.net/news/TNGX/tango-therapeu...

JUST IN: ( NASDAQ: #TNGX ) Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

#StockMarket #News

#TNGX Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/TNGX/tango-therapeu...

Breaking News: ( NASDAQ: #TNGX ) Objective long/short (TNGX) Report

#StockMarket #News